Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 1

Status

Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 3Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Demyelinating Diseases 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × ravulizumab × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT03920293 2024-05-28

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
175 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡